{"nctId":"NCT03237065","briefTitle":"Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia","startDateStruct":{"date":"2017-10-30","type":"ACTUAL"},"conditions":["Iron Deficiency Anaemia","Iron Deficiency Anemia"],"count":122,"armGroups":[{"label":"Iron isomaltoside/ferric derisomaltose","type":"EXPERIMENTAL","interventionNames":["Drug: Iron isomaltoside/ferric derisomaltose"]},{"label":"Ferric carboxymaltose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ferric carboxymaltose"]}],"interventions":[{"name":"Iron isomaltoside/ferric derisomaltose","otherNames":["Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®"]},{"name":"Ferric carboxymaltose","otherNames":["Injectafer®, Ferinject®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria include:\n\n* Subjects having IDA caused by different aetiologies\n* Haemoglobin (Hb) ≤ 11 g/dL\n* Body weight \\> 50 kg\n* Serum ferritin (S-ferritin) \\< 100 ng/mL\n* Estimated Glomerular Filtration Rate (eGFR) ≥ 65 mL/min/1.73 m2\n* Serum phosphate (S-phosphate) \\> 2.5 mg/dL\n* Intolerance or unresponsiveness to oral iron\n* Willingness to participate and signing the Informed Consent Form (ICF)\n\nExclusion criteria include:\n\n* Acute bleeding \\> 500 mL within 72 hours\n* Anaemia predominantly caused by factors other than IDA\n* Hemochromatosis or other iron storage disorders\n* Previous serious hypersensitivity reactions to any IV iron compounds\n* Treatment with IV iron within the last 30 days prior to screening\n* Treatment with erythropoietin or erythropoietin-stimulation agents\n* Red blood cell transfusion, radiotherapy, and/or chemotherapy\n* Received an investigational drug within the last 30 days prior to screening\n* Planned surgical procedure within the trial period\n* Hepatic enzymes \\> 3 times upper limit of normal\n* Surgery under anaesthetic within the last 30 days prior to screening\n* Any non-viral infection within the last 30 days prior to screening\n* Alcohol or drug abuse within the past 6 months\n* Vitamin D deficiency\n* Untreated hyperparathyroidism\n* Kidney transplantation\n* Active malignant disease, disease-free for less than 5 years\n* History of a psychological illness or seizures\n* Pregnant or nursing women.","healthyVolunteers":false,"sex":"ALL","genderBased":true,"minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)","description":"Safety\n\nThe incidence of hypophosphatemia (defined as s-phosphate \\<2 mg/dL) at any time from baseline up to day 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL)","description":"Safety\n\nTime with hypophosphatemia (i.e. time with s-phosphate level \\< 2.0 mg/dL) from baseline up to day 35.\n\nThe time with hypophosphatemia was calculated as the actual number of days from the first day where s-phosphate was \\<2 mg/dL until the first day when s-phosphate was ≥2 mg/dL. If the subject did not reach s-phosphate ≥2 mg/dL, the subject was regarded as censored on day 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Hypophosphatemia on Day 35 (S-phosphate Level <2.0 mg/dL)","description":"Safety\n\nEvaluate the proportion of subjects with hypophosphatemia (s-phosphate level \\<2.0 mg/dL) on day 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute [∆] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35","description":"Safety\n\nAbsolute \\[∆\\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.57"},{"groupId":"OG001","value":"-0.18","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.57"},{"groupId":"OG001","value":"-0.89","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.64"},{"groupId":"OG001","value":"-1.14","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.60"},{"groupId":"OG001","value":"-1.47","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.66"},{"groupId":"OG001","value":"-1.27","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.49"},{"groupId":"OG001","value":"-0.99","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Relative [%] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35","description":"Safety\n\nRelative \\[%\\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.89","spread":"16.02"},{"groupId":"OG001","value":"-4.34","spread":"15.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.99","spread":"15.38"},{"groupId":"OG001","value":"-25.83","spread":"20.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.32","spread":"18.50"},{"groupId":"OG001","value":"-33.36","spread":"19.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.66","spread":"16.27"},{"groupId":"OG001","value":"-43.54","spread":"22.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"19.15"},{"groupId":"OG001","value":"-37.71","spread":"24.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.88","spread":"14.19"},{"groupId":"OG001","value":"-28.63","spread":"28.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fractional Phosphate Urinary Excretion","description":"Safety\n\nChange in absolute fractional phosphate urinary excretion from baseline to days 1, 7, 8, 14, 21, and 35.\n\nFractional excretion of phosphate (FEPi) is calculated as (\\[phosphate in urine X creatinine in serum\\]/\\[phosphate in serum X creatinine in urine\\]) X 100, and the unit is %.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"4.26"},{"groupId":"OG001","value":"1.77","spread":"5.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"5.04"},{"groupId":"OG001","value":"4.90","spread":"6.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"5.18"},{"groupId":"OG001","value":"6.05","spread":"5.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"4.59"},{"groupId":"OG001","value":"8.50","spread":"8.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"4.18"},{"groupId":"OG001","value":"6.42","spread":"6.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"4.96"},{"groupId":"OG001","value":"5.21","spread":"7.74"}]}]}]},{"type":"SECONDARY","title":"Change in Concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) From Baseline to Day 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) from baseline to day 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.18","spread":"18.20"},{"groupId":"OG001","value":"93.38","spread":"88.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.97","spread":"45.44"},{"groupId":"OG001","value":"33.60","spread":"57.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.09","spread":"36.06"},{"groupId":"OG001","value":"259.16","spread":"210.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.35","spread":"24.09"},{"groupId":"OG001","value":"74.07","spread":"90.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.13","spread":"28.95"},{"groupId":"OG001","value":"54.49","spread":"74.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.17","spread":"23.87"},{"groupId":"OG001","value":"10.52","spread":"39.94"}]}]}]},{"type":"SECONDARY","title":"Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in C-terminal Fibroblast Growth Factor 23 (cFGF23) from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-677.38","spread":"758.35"},{"groupId":"OG001","value":"-843.21","spread":"1756.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-692.44","spread":"800.04"},{"groupId":"OG001","value":"-924.44","spread":"1748.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-753.40","spread":"803.63"},{"groupId":"OG001","value":"-853.50","spread":"1877.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-740.37","spread":"822.35"},{"groupId":"OG001","value":"-925.02","spread":"1783.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-743.99","spread":"805.24"},{"groupId":"OG001","value":"-986.30","spread":"1815.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-737.46","spread":"791.86"},{"groupId":"OG001","value":"-943.91","spread":"1741.96"}]}]}]},{"type":"SECONDARY","title":"Change in Vitamin 25-Hydroxyvitamin D (Vitamin D 25) From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in vitamin 25-Hydroxyvitamin D (vitamin D 25) from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"1.86"},{"groupId":"OG001","value":"-0.25","spread":"2.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"3.17"},{"groupId":"OG001","value":"0.61","spread":"3.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.92","spread":"3.51"},{"groupId":"OG001","value":"0.83","spread":"3.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":"4.11"},{"groupId":"OG001","value":"0.67","spread":"3.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"4.65"},{"groupId":"OG001","value":"0.13","spread":"4.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"6.10"},{"groupId":"OG001","value":"-0.66","spread":"4.60"}]}]}]},{"type":"SECONDARY","title":"Change in 1,25-Dihydroxyvitamin D (Vitamin D 1.25) From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in 1,25-Dihydroxyvitamin D (vitamin D 1.25) from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.89","spread":"10.60"},{"groupId":"OG001","value":"-16.97","spread":"13.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.78","spread":"17.81"},{"groupId":"OG001","value":"-23.92","spread":"30.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.93","spread":"17.81"},{"groupId":"OG001","value":"-35.59","spread":"26.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"16.54"},{"groupId":"OG001","value":"-36.14","spread":"26.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"16.11"},{"groupId":"OG001","value":"-24.02","spread":"29.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"15.33"},{"groupId":"OG001","value":"-12.67","spread":"25.01"}]}]}]},{"type":"SECONDARY","title":"Change in 24,25-Dihydroxyvitamin D (Vitamin D 24.25) From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in 24,25-Dihydroxyvitamin D (vitamin D 24.25) from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.45"},{"groupId":"OG001","value":"0.07","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.84"},{"groupId":"OG001","value":"0.26","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.84"},{"groupId":"OG001","value":"0.38","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.75"},{"groupId":"OG001","value":"0.55","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.55"},{"groupId":"OG001","value":"0.50","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.77"},{"groupId":"OG001","value":"0.23","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Change in Intact Parathyroid Hormone (PTH) From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in intact Parathyroid hormone (PTH) from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"18.93"},{"groupId":"OG001","value":"-7.02","spread":"25.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.72","spread":"24.41"},{"groupId":"OG001","value":"0.73","spread":"29.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"21.03"},{"groupId":"OG001","value":"-3.26","spread":"27.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":"24.17"},{"groupId":"OG001","value":"22.22","spread":"31.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"19.36"},{"groupId":"OG001","value":"22.80","spread":"38.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"22.86"},{"groupId":"OG001","value":"22.19","spread":"33.21"}]}]}]},{"type":"SECONDARY","title":"Change in Ionized Calcium From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Safety\n\nChange in ionized calcium from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.002","spread":"0.198"},{"groupId":"OG001","value":"0.047","spread":"0.168"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.206"},{"groupId":"OG001","value":"-0.003","spread":"0.219"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.206"},{"groupId":"OG001","value":"-0.016","spread":"0.186"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.090","spread":"0.500"},{"groupId":"OG001","value":"-0.054","spread":"0.251"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.030","spread":"0.204"},{"groupId":"OG001","value":"-0.016","spread":"0.194"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.012","spread":"0.212"},{"groupId":"OG001","value":"-0.015","spread":"0.211"}]}]}]},{"type":"SECONDARY","title":"Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions","description":"Safety\n\nFor this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin (Hb) Per Gram Iron From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Efficacy\n\nChange in hemoglobin (Hb) per gram iron from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.80"},{"groupId":"OG001","value":"0.46","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"1.13"},{"groupId":"OG001","value":"1.41","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"1.21"},{"groupId":"OG001","value":"0.84","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"1.13"},{"groupId":"OG001","value":"1.30","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"0.97"},{"groupId":"OG001","value":"1.63","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"1.21"},{"groupId":"OG001","value":"2.00","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"Change in S-ferritin From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Efficacy\n\nChange in s-ferritin from baseline to days 1, 7, 8, 14, 21, and 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.47","spread":"81.88"},{"groupId":"OG001","value":"76.96","spread":"79.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252.39","spread":"163.85"},{"groupId":"OG001","value":"279.15","spread":"215.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219.36","spread":"148.84"},{"groupId":"OG001","value":"313.44","spread":"229.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144.39","spread":"100.06"},{"groupId":"OG001","value":"379.42","spread":"282.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.81","spread":"92.42"},{"groupId":"OG001","value":"232.59","spread":"212.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.27","spread":"70.64"},{"groupId":"OG001","value":"126.20","spread":"157.49"}]}]}]},{"type":"SECONDARY","title":"Change in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35","description":"Efficacy\n\nChange in Transferrin Saturation (TSAT) from baseline to days 1, 7, 8, 14, 21, and 35.\n\nTSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.77","spread":"53.11"},{"groupId":"OG001","value":"83.78","spread":"42.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.05","spread":"10.00"},{"groupId":"OG001","value":"12.92","spread":"28.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.27","spread":"9.59"},{"groupId":"OG001","value":"73.44","spread":"34.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.34","spread":"7.68"},{"groupId":"OG001","value":"16.74","spread":"12.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.61","spread":"9.81"},{"groupId":"OG001","value":"16.19","spread":"10.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.87","spread":"8.49"},{"groupId":"OG001","value":"14.43","spread":"9.62"}]}]}]},{"type":"POST_HOC","title":"Incidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 35","description":"Safety\n\nIncidence of s-phosphate level ≤1.0 mg/dL at any time from baseline to day 35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":62},"commonTop":["Hypophosphatemia","Blood parathyroid hormone increased","Nausea","Blood phosphorus decreased","Headache"]}}}